The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Inhaled insulin lung cancer warning riles investors

The inhaled insulin field got blitzed again today after Nektar Therapeutics  and Pfizer reported an increased number of

Boehringer boasts of late-stage drug potential

A new self-assessment from Boehringer Ingelheim comes with some considerable boasting about the potential for new therapies and new indications now in its pipeline. Pradaxa was recently...

Quark Pharma snares $27M for RNAi work

Quark Pharmaceuticals has garnered $27 million in a new round of venture financing. The RNAi developer attracted the support of SBI Asset Management and SBI Investment, subsidiaries of the

Can Big Pharma effectively develop new drugs?

When it comes to drug development, is bigger really better? That is the question Borje Eckholm, president and CEO of Investor AB--and one of AstraZeneca's biggest shareholders--poses in the London

Pfizer halts Phase III cancer trial on poor results

Pfizer's big push into cancer drugs has hit a snag. The company announced that it is halting a late-stage trial of tremelimumab for advanced melanoma after researchers concluded it was no more

Mylan CEO makes $10M in 9 months

Not bad for nine months' work. Mylan CEO and Vice Chairman Robert Coury (photo) brought down $10.3 million during fiscal 2007,

EU adviser: GSK broke antitrust laws

Here's a big strike against one strategy for protecting drug prices. A European Union advocate general said GlaxoSmithKline violated antitrust laws when it refused to fill Greek wholesalers' orders

Analysts put BMS on takeover menu

Analysts are salivating over Bristol-Myers Squibb. Healthy earnings and sales growth, coupled with a stock price down by about a third since last July, makes the drugmaker "an attractive takeover

What's Shire doing to support Vyvanse?

Are worries about Shire's Adderall successor justified? The Wall Street Journal Health Blog asked

CFOs are pharma's new power players

Who's pharma's power forward these days? The CFO. Or so concludes Ernst & Young after slicing and dicing two global surveys. As companies shift focus from driving sales growth to managing